Search Results - "Barry, William"

Methods for studying metabolism in Drosophila by Tennessen, Jason M., Barry, William E., Cox, James, Thummel, Carl S.

“…Recent research using Drosophila melanogaster has seen a resurgence in studies of metabolism and physiology. This review focuses on major methods used to…”
Get full text

Growing Use of Contralateral Prophylactic Mastectomy Despite no Improvement in Long-term Survival for Invasive Breast Cancer by Wong, Stephanie M, Freedman, Rachel A, Sagara, Yasuaki, Aydogan, Fatih, Barry, William T, Golshan, Mehra

“…To update and examine national temporal trends in contralateral prophylactic mastectomy (CPM) and determine whether survival differed for invasive breast…”
Get full text

Survival Benefit of Breast Surgery for Low-Grade Ductal Carcinoma In Situ: A Population-Based Cohort Study by Sagara, Yasuaki, Mallory, Melissa Anne, Wong, Stephanie, Aydogan, Fatih, DeSantis, Stephen, Barry, William T, Golshan, Mehra

“…While the prevalence of ductal carcinoma in situ (DCIS) of the breast has increased substantially following the introduction of breast-screening methods, the…”
Get more information

Growing Use of Contralateral Prophylactic Mastectomy Despite no Improvement in Long-term Survival for Invasive Breast Cancer by Wong, Stephanie M, Freedman, Rachel A, Sagara, Yasuaki, Aydogan, Fatih, Barry, William T, Golshan, Mehra

“…OBJECTIVE:To update and examine national temporal trends in contralateral prophylactic mastectomy (CPM) and determine whether survival differed for invasive…”
Get full text

Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis by Barroso-Sousa, Romualdo, Barry, William T, Garrido-Castro, Ana C, Hodi, F Stephen, Min, Le, Krop, Ian E, Tolaney, Sara M

“…If not promptly recognized, endocrine dysfunction can be life threatening. The incidence and risk of developing such adverse events (AEs) following the use of…”
Get more information

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study by Liu, Joyce F, Dr, Barry, William T, PhD, Birrer, Michael, MD, Lee, Jung-Min, MD, Buckanovich, Ronald J, MD, Fleming, Gini F, Prof, Rimel, BJ, MD, Buss, Mary K, MD, Nattam, Sreenivasa, MD, Hurteau, Jean, MD, Luo, Weixiu, MS, Quy, Philippa, MA, Whalen, Christin, BSN, Obermayer, Lisa, BA, Lee, Hang, PhD, Winer, Eric P, Prof, Kohn, Elise C, MD, Ivy, S Percy, MD, Matulonis, Ursula A, MD

“…Summary Background Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is an anti-angiogenic agent with activity against VEGF receptor (VEGFR) 1,…”
Get full text

The Drosophila HNF4 nuclear receptor promotes glucose-stimulated insulin secretion and mitochondrial function in adults by Barry, William E, Thummel, Carl S

“…Although mutations in HNF4A were identified as the cause of Maturity Onset Diabetes of the Young 1 (MODY1) two decades ago, the mechanisms by which this…”
Get full text

Patterns of recurrence and metastasis in BRCA1/BRCA2‐associated breast cancers by Song, Yun, Barry, William T., Seah, Davinia S., Tung, Nadine M., Garber, Judy E., Lin, Nancy U.

“…Background Breast cancer subtypes are associated with distinct metastatic patterns. Whether germline BRCA1/BRCA2 mutation status is independently associated…”
Get full text

Impact of neoadjuvant chemotherapy and pathological complete response on eligibility for breast-conserving surgery in patients with early breast cancer: A meta-analysis by Criscitiello, Carmen, Golshan, Mehra, Barry, William T., Viale, Giulia, Wong, Stephanie, Santangelo, Michele, Curigliano, Giuseppe

“…We conducted a meta-analysis of randomised trials evaluating pathological complete response (pCR) and surgical outcomes after neoadjuvant systemic therapy…”
Get full text

Breast cancer‐specific survival by age: Worse outcomes for the oldest patients by Freedman, Rachel A., Keating, Nancy L., Lin, Nancy U., Winer, Eric P., Vaz‐Luis, Ines, Lii, Joyce, Exman, Pedro, Barry, William T.

“…BACKGROUND Although breast cancer often is perceived to be indolent in older women, breast cancer outcomes in the oldest patients are variable. In the current…”
Get full text

Patient Prognostic Score and Associations With Survival Improvement Offered by Radiotherapy After Breast-Conserving Surgery for Ductal Carcinoma In Situ: A Population-Based Longitudinal Cohort Study by Sagara, Yasuaki, Freedman, Rachel A, Vaz-Luis, Ines, Mallory, Melissa Anne, Wong, Stephanie M, Aydogan, Fatih, DeSantis, Stephen, Barry, William T, Golshan, Mehra

“…Radiotherapy (RT) after breast-conserving surgery (BCS) is a standard treatment option for the management of ductal carcinoma in situ (DCIS). We sought to…”
Get full text

Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer by Tolaney, Sara M, Barry, William T, Dang, Chau T, Yardley, Denise A, Moy, Beverly, Marcom, P. Kelly, Albain, Kathy S, Rugo, Hope S, Ellis, Matthew, Shapira, Iuliana, Wolff, Antonio C, Carey, Lisa A, Overmoyer, Beth A, Partridge, Ann H, Guo, Hao, Hudis, Clifford A, Krop, Ian E, Burstein, Harold J, Winer, Eric P

“…A multicenter single-group trial suggests that adjuvant therapy with paclitaxel plus trastuzumab lowers the risk of relapse in women with small HER2-positive…”
Get full text

Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients by Tolaney, Sara M., Boucher, Yves, Duda, Dan G., Martin, John D., Seano, Giorgio, Ancukiewicz, Marek, Barry, William T., Goel, Shom, Lahdenrata, Johanna, Isakoff, Steven J., Yeh, Eren D., Jain, Saloni R., Golshan, Mehra, Brock, Jane, Snuderl, Matija, Winer, Eric P., Krop, Ian E., Jain, Rakesh K.

“…Preoperative bevacizumab and chemotherapy may benefit a subset of breast cancer (BC) patients. To explore potential mechanisms of this benefit, we conducted a…”
Get full text

Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer by Tolaney, Sara M, Guo, Hao, Pernas, Sonia, Barry, William T, Dillon, Deborah A, Ritterhouse, Lauren, Schneider, Bryan P, Shen, Fei, Fuhrman, Kit, Baltay, Michele, Dang, Chau T, Yardley, Denise A, Moy, Beverly, Marcom, P Kelly, Albain, Kathy S, Rugo, Hope S, Ellis, Mathew J, Shapira, Iuliana, Wolff, Antonio C, Carey, Lisa A, Overmoyer, Beth, Partridge, Ann H, Hudis, Clifford A, Krop, Ian E, Burstein, Harold J, Winer, Eric P

“…The Adjuvant Paclitaxel and Trastuzumab trial was designed to address treatment of patients with small human epidermal growth factor receptor 2 (HER2)-positive…”
Get full text

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib by Carey, Lisa A, Berry, Donald A, Cirrincione, Constance T, Barry, William T, Pitcher, Brandelyn N, Harris, Lyndsay N, Ollila, David W, Krop, Ian E, Henry, Norah Lynn, Weckstein, Douglas J, Anders, Carey K, Singh, Baljit, Hoadley, Katherine A, Iglesia, Michael, Cheang, Maggie Chon U, Perou, Charles M, Winer, Eric P, Hudis, Clifford A

“…Dual human epidermal growth factor receptor 2 (HER2) targeting can increase pathologic complete response rates (pCRs) to neoadjuvant therapy and improve…”
Get full text

Bayesian Response-Adaptive Designs for Basket Trials by Ventz, Steffen, Barry, William T., Parmigiani, Giovanni, Trippa, Lorenzo

“…We develop a general class of response-adaptive Bayesian designs using hierarchical models, and provide open source software to implement them. Our work is…”
Get full text

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer by Telli, Melinda L, Timms, Kirsten M, Reid, Julia, Hennessy, Bryan, Mills, Gordon B, Jensen, Kristin C, Szallasi, Zoltan, Barry, William T, Winer, Eric P, Tung, Nadine M, Isakoff, Steven J, Ryan, Paula D, Greene-Colozzi, April, Gutin, Alexander, Sangale, Zaina, Iliev, Diana, Neff, Chris, Abkevich, Victor, Jones, Joshua T, Lanchbury, Jerry S, Hartman, Anne-Renee, Garber, Judy E, Ford, James M, Silver, Daniel P, Richardson, Andrea L

“…BRCA1/2-mutated and some sporadic triple-negative breast cancers (TNBC) have DNA repair defects and are sensitive to DNA-damaging therapeutics. Recently, three…”
Get full text

Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance) by Rugo, Hope S, Barry, William T, Moreno-Aspitia, Alvaro, Lyss, Alan P, Cirrincione, Constance, Leung, Eleanor, Mayer, Erica L, Naughton, Michael, Toppmeyer, Deborah, Carey, Lisa A, Perez, Edith A, Hudis, Clifford, Winer, Eric P

“…We compared nab-paclitaxel or ixabepilone once per week to paclitaxel with bevacizumab as first-line therapy for patients with advanced breast cancer (BC) to…”
Get full text

The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy by Waks, Adrienne G, Stover, Daniel G, Guerriero, Jennifer L, Dillon, Deborah, Barry, William T, Gjini, Evisa, Hartl, Christina, Lo, Wesley, Savoie, Jennifer, Brock, Jane, Wesolowski, Robert, Li, Zaibo, Damicis, Adrienne, Philips, Anne V, Wu, Yun, Yang, Fei, Sullivan, Amy, Danaher, Patrick, Brauer, Heather Ann, Osmani, Wafa, Lipschitz, Mikel, Hoadley, Katherine A, Goldberg, Michael, Perou, Charles M, Rodig, Scott, Winer, Eric P, Krop, Ian E, Mittendorf, Elizabeth A, Tolaney, Sara M

“…Hormone receptor-positive/HER2-negative (HR /HER2 ) breast cancer is associated with low levels of stromal tumor-infiltrating lymphocytes (sTIL) and PD-L1, and…”
Get full text

Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial by Konstantinopoulos, Panagiotis A, Barry, William T, Birrer, Michael, Westin, Shannon N, Cadoo, Karen A, Shapiro, Geoffrey I, Mayer, Erica L, O'Cearbhaill, Roisin E, Coleman, Robert L, Kochupurakkal, Bose, Whalen, Christin, Curtis, Jennifer, Farooq, Sarah, Luo, Weixiu, Eismann, Julia, Buss, Mary K, Aghajanian, Carol, Mills, Gordon B, Palakurthi, Sangeetha, Kirschmeier, Paul, Liu, Joyce, Cantley, Lewis C, Kaufmann, Scott H, Swisher, Elizabeth M, D'Andrea, Alan D, Winer, Eric, Wulf, Gerburg M, Matulonis, Ursula A

“…Based on preclinical work, we found that combination of poly (ADP-ribose) polymerase (PARP) inhibitors with drugs that inhibit the homologous recombination…”
Get full text